《Nature,6月8日,The inhibition of IL-2/IL-2R gives rise to CD8+ T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-06-09
  • The inhibition of IL-2/IL-2R gives rise to CD8+ T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia

    Hongbo Shi, Wenjing Wang, Jiming Yin, Yabo Ouyang, Lijun Pang, Yingmei Feng, Luxin Qiao, Xianghua Guo, Honglin Shi, Ronghua Jin & Dexi Chen

    Cell Death & Disease volume 11, Article number: 429 (2020)

    Abstract

    Although most patients with COVID-19 pneumonia have a good prognosis, some patients develop to severe or critical illness, and the mortality of critical cases is up to 61.5%. However, specific molecular information about immune response in critical patients with COVID-19 is poorly understood. A total of 54 patients were enrolled and divided into three groups, among which 34 were common, 14 were severe, and 6 were critical. The constitution of peripheral blood mononuclear cells (PBMC) in patients was analyzed by CyTOF. The profile of cytokines was examined in plasma of patients using luminex. The IL-2 signaling pathway was investigated in the PBMC of patients by qRT-PCR. The count and percentage of lymphocytes were significantly decreased in critical patients compared to common and severe patients with COVID-19 pneumonia.

  • 原文来源:https://www.nature.com/articles/s41419-020-2636-4
相关报告
  • 《6月8日_IL-2/IL-2R抑制剂通过JAK1-STAT5通路可以使COVID-19危重症患者的CD8+T细胞增加和淋巴细胞减少》

    • 来源专题:COVID-19科研动态监测
    • 编译者:xuwenwhlib
    • 发布时间:2020-06-09
    • 信息名称:IL-2/IL-2R抑制剂通过JAK1-STAT5通路可以使COVID-19危重症患者的CD8+T细胞增加和淋巴细胞减少 1.时间:2020年6月8日 2.机构或团队:首都医科大学、北京市精准医疗与肝炎、肝癌转化工程研究中心 3.事件概要: 首都医科大学等机构在Nature子刊Cell Death & Disease发表论文“The inhibition of IL-2/IL-2R gives rise to CD8+ T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia”。 COVID-19肺炎患者多数预后良好,但部分患者发展为重症或危重症,危重病例死亡率高达61.5%。然而,关于COVID-19重症患者免疫反应的具体分子信息尚不清楚。文章共纳入54例患者,分为三组,普通症状组34例,重症组14例,危重症组6例,利用质谱流式细胞技术分析患者外周血单核细胞(PBMC)的组成,使用luminex检测患者血浆中的细胞因子,采用qRT-PCR方法研究患者PBMC中IL-2信号通路。研究发现,COVID-19患者的PBMC中IL-2R、JAK1、STAT5表达降低,IL-2在重症患者中升高,在危重症患者中降低。文章认为,COVID-19肺炎危重症患者CD8+ T细胞减少可能与IL-2信号通路有关,IL-2/IL-2R抑制可通过JAK1-STAT5导致COVID-19肺炎重症患者CD8+ T细胞增加和淋巴细胞减少。 4.附件: 原文链接:https://www.nature.com/articles/s41419-020-2636-4
  • 《IL-2/IL-2R抑制剂通过JAK1-STAT5通路可以使COVID-19危重症患者的CD8+T细胞增加和淋巴细胞减少》

    • 来源专题:生物安全知识资源中心 | 领域情报网
    • 编译者:hujm
    • 发布时间:2020-06-22
    • 首都医科大学等机构在Nature子刊Cell Death & Disease发表论文“The inhibition of IL-2/IL-2R gives rise to CD8+ T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia”。 COVID-19肺炎患者多数预后良好,但部分患者发展为重症或危重症,危重病例死亡率高达61.5%。然而,关于COVID-19重症患者免疫反应的具体分子信息尚不清楚。文章共纳入54例患者,分为三组,普通症状组34例,重症组14例,危重症组6例,利用质谱流式细胞技术分析患者外周血单核细胞(PBMC)的组成,使用luminex检测患者血浆中的细胞因子,采用qRT-PCR方法研究患者PBMC中IL-2信号通路。研究发现,COVID-19患者的PBMC中IL-2R、JAK1、STAT5表达降低,IL-2在重症患者中升高,在危重症患者中降低。文章认为,COVID-19肺炎危重症患者CD8+ T细胞减少可能与IL-2信号通路有关,IL-2/IL-2R抑制可通过JAK1-STAT5导致COVID-19肺炎重症患者CD8+ T细胞增加和淋巴细胞减少。